People news from the 02/13/07 news brief

AGENCIES Williams-Labadie has announced new hires and promotions. Jeff Loibl has been hired as senior copywriter. Loibl joins from DDB Chicago where he worked as associate creative director and senior copywriter. Whitney Bruce has been promoted to account executive. Bruce will be working on the Astellas account. Misty Castaldi has joined Williams-Labadie as senior art director. Castaldi joins from StudioNorth. Castaldi will focus on the Araxane/Abraxis Oncology and Factive accounts. Juan Peña has been hired as senior designer. Most recently, Peña worked as designer and Web designer with Storandt Pann Margolis on both consumer and B2B accounts. Peña will contribute on projects that involve both traditional and electronic media. Chris Rocco joins as production manager/art buyer. Rocco was most recently at Protocol Integrated Direct Marketing. Chris Rogers has been promoted to art director. He will work primarily on Smith & Nephew. Kim Kardash has been promoted to associate account executive where she will continue to contribute to Abraxis Oncology. Eric Cale’s promotion to associate account executive enlarges his role in working with Prometheus Laboratories. Kim Panozzo has been promoted to account service manager and she will focus primarily on Abraxis Oncology, and Katie Flom has been hired as account assistant to take over Panozzo’s previous duties. Andrew Tutt has joined Williams-Labadie’s Ideon Healthcare Education unit as account supervisor. Tutt comes from Access Medical Group, where he worked on a wide variety of medical education programs. GSW Worldwide, an inVentiv Health company, recently named Julie Ann Schipper vice president, account director in its New York office. In this position she will be responsible for collaborating with clients on assigned accounts to develop strategic marketing plans as well as manage a supporting team. Schipper comes to GSW Worldwide with more than eight years of pharmaceutical marketing experience and over 13 years of overall advertising experience. Most recently, she served as vice president, account supervisor at FCB Healthcare where she managed accounts such as GlaxoSmithKline's Lamictal. Prior to joining FCB Healthcare, Schipper served as vice president, account supervisor at Cline, Davis & Mann where she launched Genentech's Rituxan for rheumatoid arthritis for the managed market audience. She also supervised Pfizer's Caduet account in which she initiated strategies and tactics to market the drug to managed markets. Additionally, Schipper worked in various positions, each with increasing responsibility, at Dorland Global Health Communications. While at Dorland, she managed accounts for clients including Wyeth Pharmaceuticals, Centocor Corporate, Chiron Vaccines, Rostam and Procter & Gamble Pharmaceuticals. LLNS has hired Susan Flinn as president of the agency. Flinn will be responsible for leading the overall marketing strategy and initiatives for the agency’s numerous pharmaceutical clients, as well as the company’s business development and marketing operations, reporting to Anne Devereux, CEO of both LLNS and TBWA\WorldHealth. Flinn began her career in 1987 at another Omnicom agency; Kallir, Philips, Ross with GlaxoSmithKline as her major account. Heading to Chicago in 1991, she then worked for several of the top healthcare advertising agencies in the Midwest, handling numerous billion-dollar brands including Lupron Depot, Prevacid and Imitrex, before opening the Chicago office of Euro RSCG Life in 2002.
You must be a registered member of MMM to post a comment.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.